Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Liao, Ruyi ^a,b,c   Liu, Qinghua ^a,b,c   Zheng, Zhihua ^a,b,c   Fan, Jinjin ^a,b,c   Peng, Wenxing ^a,b,c   Kong, Qingyu ^a,b,c   He, Huijuan ^a,b,c   Yang, Shicong ^a   Chen, Wenfang ^a   Tang, Xueqing ^a,b,c   Yu, Xueqing ^a,b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Provincial Key Laboratory of Food   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; CREATININE; F ACTIN; IMMUNOGLOBULIN G; LIPOCORTIN 5; MESSENGER RNA; NITROGEN; SYNAPTOPODIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; UREA; WT1 PROTEIN; ACTIN BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; SYNPO PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOSKELETON; DRUG MECHANISM; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; TRANSMISSION ELECTRON MICROSCOPY; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL PROTECTION; DRUG EFFECTS; FEMALE; KIDNEY; LUPUS NEPHRITIS; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PROTEIN STABILITY;

ANIMALS; APOPTOSIS; CELL LINE; COMPLEMENT C3; CYTOPROTECTION; CYTOSKELETON; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; MICE, INBRED MRL LPR; MICROFILAMENT PROTEINS; PODOCYTES; PROTEIN STABILITY; PROTEINURIA; TACROLIMUS;

EID: 84941336343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132724     Document Type: Article

References (32)

1. Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis. J Int Med Res. 2009; 37: 892-898. PMID: 19589275
2. Yoon KH. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol. 2010; 2010: 686480. doi: 10.1155/2010/686480 PMID: 20625508
3. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011; 57: 235-244. doi: 10.1053/j.ajkd.2010.08.036 PMID: 21177013
4. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008; 14: 931-938. doi: 10.1038/nm.1857 PMID: 18724379
5. Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J Immunol. 2012; 188: 3628-3638. doi: 10. 4049/jimmunol.1102859 PMID: 22407922
6. White KE, Bilous RW. Estimation of podocyte number: a comparison of methods. Kidney Int. 2004; 66: 663-667. PMID: 15253720
7. Mundel P, Reiser J, Kriz W. Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol. 1997; 8: 697-705. PMID: 9176839
8. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int. 2010; 77: 71-80.
9. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40: 1256-1265.
10. Li X, Li H, Ye H, Li Q, He X, Zhang X, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide- resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis. 2009; 54: 51-58. doi: 10.1053/j.ajkd.2009.02.018 PMID: 19406543
11. Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron. 1993; 64: 471-475. PMID: 7688103
12. Perysinaki GS, Moysiadis DK, Bertsias G, Giannopoulou I, Kyriacou K, Nakopoulou L, et al. Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology. Lupus. 2011; 20: 781-791. doi: 10.1177/0961203310397412 PMID: 21478284
13. Mundel P, Heid HW, Mundel TM, Krüger M, Reiser J, Kriz W. Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol. 1997; 139: 193-204. PMID: 9314539
14. Srivastava T, Garola RE, Whiting JM, Alon US. Synaptopodin expression in idiopathic nephrotic syndrome of childhood. Kidney Int. 2001; 59: 118-125. PMID: 11135064
15. Olin AI, Mörgelin M, Truedsson L, Sturfelt G, Bengtsson AA. Pathogenic mechanisms in lupus nephritis: Nucleosomes bind aberrant laminin β1 with high affinity and colocalize in the electron-dense deposits. Arthritis Rheumatol. 2014; 66: 397-406. doi: 10.1002/art.38250 PMID: 24504812
16. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 1996; 49: 461-469. PMID: 8821830
17. Yamamoto K, Loskutoff DJ. Expression of transforming growth factor-beta and tumor necrosis factoralpha in the plasma and tissues of mice with lupus nephritis. Lab Invest. 2000; 80: 1561-1570. PMID: 11045573
18. Herman-Edelstein M, Weinstein T, Gafter U. TGFβ1-dependent podocyte dysfunction. Curr Opin Nephrol Hypertens. 2013; 22: 93-99. doi: 10.1097/MNH.0b013e32835b4870 PMID: 23132369
19. Su J, Li SJ, Chen ZH, Zeng CH, Zhou H, Li LS, et al. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract. 2010; 87: 167-175. doi: 10.1016/j.diabres.2009.10.022 PMID: 19969384
20. Kanemoto K, Takahashi S, Shu Y, Usui J, Tomari S, Yan K, et al. Variable expression of podocyterelated markers in the glomeruloid bodies in Wilms tumor. Pathol Int. 2003; 53: 596-601. PMID: 14507316
21. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006; 69: 2131-2147. PMID: 16688120
22. He FF, Zhang C, Chen S, Deng BQ, Wang H, Shao N, et al. Role of CD2-associated protein in albumin overload-induced apoptosis in podocytes. Cell Biol Int. 2011; 35: 827-834. doi: 10.1042/CBI20100411 PMID: 21166652
23. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995; 267: 1456-1462. PMID: 7878464
24. Das R, Xu S, Quan X, Nguyen TT, Kong ID, Chung CH, et al. Upregulation of mitochondrial Nox4 mediates TGF-β-induced apoptosis in cultured mouse podocytes. Am J Physiol Renal Physiol. 2014; 306: F155-167. doi: 10.1152/ajprenal.00438.2013 PMID: 24259511
25. Walter DH, Haendeler J, Galle J, Zeiher AM, Dimmeler S. Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. Circulation. 1998; 98: 1153-1157. PMID: 9743504
26. Lotem J, Sachs L. Different mechanisms for suppression of apoptosis by cytokines and calcium mobilizing compounds. Proc Natl Acad Sci USA. 1998; 95: 4601-4606. PMID: 9539784
27. Fornoni A, Li H, Foschi A, Striker GE, Striker LJ. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporine A-induced apoptosis. Am J Pathol. 2001; 158: 275-280. PMID: 11141501
28. Schönenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant. 2011; 26: 18-24. doi: 10.1093/ndt/gfq617 PMID: 20937691
29. Zhao Z, Weinstein E, Tuzova M, Davidson A, Mundel P, Marambio P, et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum. 2005; 52: 522-530. PMID: 15693007
30. Suzuki N, Sakane T, Tsunematsu T. Effects of a novel immunosuppressive agent, FK506, on human B cell activation. Clin Exp Immunol. 1990; 79: 240-245. PMID: 1690097
31. Glynne R, Akkaraju S, Healy JI, Rayner J, Goodnow CC, Mack DH. How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis. Nature. 2000; 403: 672-676. PMID: 10688206
32. Quinn DG, Fennell JS, Sheils O, Gaffney EF, Feighery CF. Effect of cyclosporin on immune complex deposition in murine glomerulonephritis. Immunology. 1991; 72: 550-554. PMID: 1828056